Quality of life differences between responders and nonresponders in the treatment of cutaneous

JAMA Dermatology

Volumn 149, Issue 1, 2013, Pages 104-106

  Chang, Aileen Y ^a,b   Ghazi, Elizabeth ^a,b,c   Okawa, Joyce ^a,b   Werth, Victoria P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; HYDROXYCHLOROQUINE; MEPACRINE; METHOTREXATE; MYCOPHENOLIC ACID;

CLASI; CLINICAL ARTICLE; EMOTION; FUNCTIONAL STATUS; HUMAN; LETTER; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SKIN LUPUS ERYTHEMATOSUS; SKINDEX 29; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84873479669     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.467     Document Type: Letter

References (6)

1. Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;64(5):849-858.
2. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889-894.
3. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433- 1440. (Pubitemid 27490569)
4. Sontheimer RD. The lexicon of cutaneous lupus erythematosus: a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997;6(2):84-95. (Pubitemid 27102035)
5. Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147(11):1261-1267.
6. Klein R, Moghadam-Kia S, Lo Monico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203-208.